OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study

BACKGROUND: OnabotulinumtoxinA has proven its efficacy in reducing the number of headache days in chronic migraine (CM) patients. The usual paradigm includes 31 pericranial injection sites with low dose (5 U) per site. The aim of this study is to present the results obtained using a simpler injectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranoux, Danièle, Martiné, Gaelle, Espagne-Dubreuilh, Gaëlle, Amilhaud-Bordier, Marlène, Caire, François, Magy, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520828/
https://www.ncbi.nlm.nih.gov/pubmed/28733943
http://dx.doi.org/10.1186/s10194-017-0781-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520828/
https://www.ncbi.nlm.nih.gov/pubmed/28733943
http://dx.doi.org/10.1186/s10194-017-0781-7

Ejemplares similares